TRIM21 and COVID-19: A meta-analysis revealed that the development of primary rheumatic diseases associated with patients with COVID-19 were vasculitis, arthritis, idiopathic inflammatory myopathies, and systemic lupus erythematosus; overall, the association between antinuclear antibodies and COVID-19 infection was 35.6%, and the reactive antigens were found at the following rates: SSA (25%), rheumatoid factor (19%), lupus anticoagulant (11%), and IFN-I (10%) (11).